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Increasing resistance of microorganisms to currently available
antimicrobial drugs is the major cause of morbidity and mortal-
ity throughout theworld. Thus development of novel antimicro-
bial drugs is still in demand. The compounds carrying
azomethine functional group –C‚N– which are known as24 2474033.
.M. Isloor).
y. Production and hosting by
Saud University.
lsevierSchiff bases have gained importance in medicinal and pharma-
ceutical ﬁelds due to the most versatile organic synthetic inter-
mediates and also showing a broad range of biological
activities, such as antituberculosis (Patole et al., 2006; Hearn
and Cynamon, 2004), anticancer (Ren et al., 2002), analgesic
and anti-inﬂammatory (Bhandari et al., 2008), anticonvulsant
(Sridhar et al., 2002; Kaplan et al., 1980) antibacterial and anti-
fungal activities (Shi et al., 2007). These Schiff bases are good
intermediates for the synthesis ofmanyheterocyclic ring systems
like thiazolidinones (Kucukguzel et al., 2006), azetidinones
(Kalsi et al., 1990) etc. The chemistry of 1,2,4-triazole and its
fused heterocyclic derivatives has received considerable atten-
tion owing to their synthetic and effective biological importance.
1,2,4-Triazole moieties have been incorporated into a variety of
therapeutically interesting drug candidates including antiviral
(ribavarin), antimigraine (rizatriptan), antifungal (ﬂucanazole),
antianxiety compounds (alprazolam).Moreover sulfur contain-
ing heterocyclic compounds represent an important group of
compounds that are promising on practical application (Holla
336 S. Malladi et al.et al., 2003; Wu et al., 2007). The pharmacological importance
of heterocycles derived from 1,2,4-triazole paved the way to-
wards active research in a triazole chemistry. Pyrazoles repre-
sent a key motif in heterocyclic chemistry and occupy a prime
place inmedicinal and pesticide chemistry due to their capability
to exhibit a wide range of bioactivities, such as antimicrobial
(Sultivan et al., 2007; Gilbert et al., 2006; Prakash et al., 2009;
Isloor et al., 2009), anticancer (Magedov et al., 2007), anti-
inﬂammatory (Szabo et al., 2008; Benaamane et al., 2008),
antidepressant (Prasad et al., 2005), anticonvulsant (Ozdemir
et al., 2007), antipyretic (Sener et al., 2002), selective enzyme
inhibitory activities (Wachter et al., 1996) etc. Amongst a large
array ofmedicinally important pyrazole derivatives, 4-function-
alized pyrazoles occupy a unique position and their evaluation
as antimicrobial agents has attracted much attention in the past
(Prakash et al., 2009; Sridhar et al., 2004; Bekhit et al., 2003;
Bekhit et al., 2008; Vijesh et al., 2010). Pyrazoles with various
functional groups at position-4, such as cyano or oxime (Prak-
ash et al., 2009), aldehyde or carboxylate (Sridhar et al., 2004)
have been known to show good antimicrobial properties. In
view of these and in continuation of our research on biologically
active molecules, we hereby report the synthesis of some new
Schiff bases bearing triazole and pyrazole moieties and their
antibacterial studies.
2. Experimental
2.1. Measurements
Melting points were determined by open capillary method and
are uncorrected. The IR spectra (in KBr pellets) were recorded
on a Thermo Nicolet avatar 330-FT-IR spectrophotometer. 1H
NMR spectra were recorded (DMSO-d6) on a Bruker
(400 MHz) spectrometer using TMS as internal standard.
Chemical shift values are given in d scales. The mass spectra
were recorded on LC–MS-Agilent 1100 series and API 2000
LC/MS system. Elemental analyses were performed on a Flash
EA 1112 series CHNS-O analyser. The completion of the
reaction was checked by thin layer chromatography (TLC)
on silica gel coated aluminium sheets (silica gel 60 F254). Com-
mercial grade solvents and reagents were used without further
puriﬁcation. The reaction pathway has been summarized in
Scheme 1.
2.2. Synthesis
2.2.1. Synthesis of 4-amino-5-substituted-4H-1,2,4-triazole-3-
thiol 1a–c
The compounds were synthesized according to previously re-
ported procedure (Isloor et al., 2009).
2.2.2. Synthesis of 3-(4-substitutedphenyl)-1H-pyrazole-4-
carbaldehyde 2a–e
The compounds were synthesized according to previously re-
ported procedure (Lebedev et al., 2005).
2.2.3. General procedure for the synthesis of 4-[(3-substituted-
1H-pyrazol-3-yl)methyleneamino]-5-substituted-4H-1,2,4-
triazole-3-thiols 3a–j
An equimolar mixture of 4-amino-5-substituted-4H-1,2,4-
triazole-3-thiol 1a–c (0.001 mol) and 3-(4-substitutedphenyl)-1H-pyrazole-4-carbaldehyde 2a–e (0.001 mol) was reﬂuxed in
ethanol-dioxane mixture for 7 h in the presence of a catalytic
amount of concentrated sulfuric acid. The resulting solution
was cooled to room temperature and the precipitated solid
was ﬁltered under suction, washed with ethanol and recrystal-
lised from ethanol-dioxane mixture.
2.3. Characterization of synthesized compounds
2.3.1. 5-Ethyl-4-{[(E)-(3-phenyl-1H-pyrazol-4-yl)methyli-
dene]amino}-4H-1,2,4-triazole-3-thiol 3a
Yield 79%, m.p. 217–219 C. IR (cm1): 3094 (N–H), 3035
(Ar–H), 2916 (C–H), 1584 (C‚N). 1H NMR (DMSO-d6)
d = 13.67 (br s, 2H, SH&NH), 9.76 (s, 1H, N‚CH), 8.23 (s,
1H, pyrazole-5H), 7.5–7.75 (m, 5H, Ar–H), 2.69 (q, 2H, –
CH2), 1.21 (t, 3H, –CH3). MS [EI] m/z 299 [M+1]. Elemental
analysis (C14H14N6S); calcd. C, 56.36; H, 4.73; N, 28.17; found
C, 56.29; H, 4.68; N, 28.11%.
2.3.2. 5-Ethyl-4-({(E)-[3-(4-methoxyphenyl)-1H-pyrazol-4-
yl]methylidene}amino)-4H-1,2,4-triazole-3-thiol 3b
Yield 65%, m.p. 227–229 C. IR (cm1): 3103 (N–H), 3013
(Ar–H), 2929 (C–H), 1603 (C‚N), 1169 (C–O). 1H NMR
(DMSO-d6) d = 13.66 (br s, 2H, SH&NH), 9.68 (s, 1H,
N‚CH), 8.26 (s, 1H, pyrazole-5H), 7.67 (d, 2H, J = 8.4 Hz,
Ar–H), 7.0 (d, 2H, J = 8.4 Hz, Ar–H), 3.82 (s, 3H, –OCH3),
2.67 (q, 2H, –CH2), 1.21 (t, 3H, –CH3). MS [EI] m/z 329
[M+1]. Elemental analysis (C15H16N6OS); calcd. C, 54.86; H,
4.91; N, 25.59; found C, 54.81; H, 4.88; N, 25.53%.
2.3.3. 5-Ethyl-4-({(E)-[3-(4-ﬂuorophenyl)-1H-pyrazol-4-
yl]methylidene}amino)-4H-1,2,4-triazole-3-thiol 3c
Yield 63%, m.p. 242–244 C. IR (cm1): 3109 (N–H), 3054
(Ar–H), 2877 (C–H), 1599 (C‚N), 1157 (C–F). 1H NMR
(DMSO-d6) d = 13.68 (br s, 2H, SH&NH), 9.72 (s, 1H,
N‚CH), 8.4 (s, 1H, pyrazole-5H), 7.35–7.80 (m, 4H, Ar–H),
2.65 (q, 2H, –CH2), 1.19 (t, 3H, –CH3). MS [EI] m/z 317
[M+1]. Elemental analysis (C14H13FN6S); calcd. C, 53.15;
H, 4.14; N, 26.57; found C, 53.11; H, 4.09; N, 26.52%.
2.3.4. 4-({(E)-[3-(4-Chlorophenyl)-1H-pyrazol-4-yl]methyli-
dene}amino)-5-ethyl-4H-1,2,4-triazole-3-thiol 3d
Yield 67%, m.p. 248–250 C. IR (cm1): 3129 (N–H), 3078
(Ar–H), 2911 (C–H), 1597 (C‚N), 831 (C–Cl). 1H NMR
(DMSO-d6) d = 13.69 (br s, 2H, SH&NH), 9.76 (s, 1H,
N‚CH), 8.57 (s, 1H, pyrazole-5H), 7.75 (d, 2H, J = 8.4 Hz,
Ar–H), 7.57 (d, 2H, J = 8.4 Hz, Ar–H), 2.65 (q, 2H, –CH2),
1.19 (t, 3H, –CH3). MS [EI] m/z 333 [M+1]. Elemental analy-
sis (C14H13ClN6S); calcd. C, 50.52; H, 3.94; N, 25.25; found C,
50.47; H, 3.88; N, 25.19%.
2.3.5. 4-({(E)-[3-(2,4-Dichlorophenyl)-1H-pyrazol-4-
yl]methylidene}amino)-5-ethyl-4H-1,2,4-triazole-3-thiol 3e
Yield 64%, m.p. 238–240 C. IR (cm1): 3125(N–H), 3051
(Ar–H), 2974 (C–H), 1596 (C‚N), 853 (C–Cl). 1H NMR
(DMSO-d6) d = 13.67 (br s, 2H, SH&NH), 9.74 (s, 1H,
N‚CH), 8.54 (s, 1H, pyrazole-5H), 8.0 (d, 1H, J= 7.8 Hz,
Ar–H), 7.56 (d, 1H, J= 2.8 Hz, Ar–H), 7.45 (m, 1H, Ar–H).
MS [EI] m/z 366 [M+]. Elemental analysis (C14H12Cl2N6S);
calcd. C, 45.79; H, 3.29; N, 22.88; found C, 45.73; H, 3.22;
N, 22.83%.
Scheme 1 Synthetic route for the new Schiff bases.
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amino}-4H-1,2,4-triazole-3-thiol 3f
Yield 69%, m.p. 253–255 C. IR (cm1): 3138 (N–H), 3014
(Ar–H), 2971 (C–H), 1569 (C‚N). 1H NMR (DMSO-d6)
d = 13.8 (s, 1H, SH), 13.75 (br s, 1H, NH), 9.54 (s, 1H,
N‚CH), 8.77 (s, 1H, triazole-5H), 8.13 (s, 1H, pyrazole-5H),
7.52–7.75 (m, 5H, Ar–H), 3.82 (s, 3H, –OCH3). MS [EI] m/z
271 [M+1]. Elemental analysis (C12H10N6S); calcd. C, 53.32;
H, 3.73; N, 31.09; found C, 53.27; H, 3.68; N, 31.14%.
2.3.7. 4-({(E)-[3-(4-Methoxyphenyl)-1H-pyrazol-4-yl]methyli-
dene}amino)-4H-1,2,4-triazole-3-thiol 3g
Yield 66%, m.p. 244–246 C. IR (cm1): 3137 (N–H), 3067
(Ar–H), 2935(C–H), 1598 (C‚N), 1167 (C–O). 1H NMR
(DMSO-d6) d = 13.89 (s, 1H, SH), 13.68 (br s, 1H, NH),
9.47 (s, 1H, N‚CH), 8.78 (s, 1H, triazole-5H), 8.13 (s, 1H,
pyrazole-5H), 7.66 (d, 2H, J = 6.8 Hz, Ar–H), 7.09 (d, 2H,
J= 8.4 Hz, Ar–H), 3.82 (s, 3H, –OCH3). MS [EI] m/z 301
[M+1]. Elemental analysis (C13H12N6OS); calcd. C, 51.99;
H, 4.03; N, 27.98; found 51.93; H, 4.06; N, 27.91%.
2.3.8. 4-({(E)-[3-(4-Fluorophenyl)-1H-pyrazol-4-yl]methyli-
dene}amino)-4H-1,2,4-triazole-3-thiol 3h
Yield 63%, m.p. 276–278 C. IR (cm1): 3139 (N–H), 3072
(Ar–H), 2969 (C–H), 1600 (C‚N), 1148 (C–F). 1H NMR
(DMSO-d6) d = 13.90 (s, 1H, SH), 13.76 (br s, 1H, NH),
9.48 (s, 1H, N‚CH), 8.79 (s, 1H, triazole-5H), 8.20 (s, 1H,
pyrazole-5H), 7.35–7.83 (m, 4H, Ar–H). MS [EI] m/z 289
[M+1]. Elemental analysis (C12H9FN6S); calcd. C, 49.99; H,
3.15; N, 29.15; found C, 49.94; H, 3.11; N, 29.12%.2.3.9. 4-({(E)-[3-(4-Chlorophenyl)-1H-pyrazol-4-yl]methyli-
dene}amino)-4H-1,2,4-triazole-3-thiol 3i
Yield 76%, m.p. 283–285 C. IR (cm1): 3131 (N–H), 3021
(Ar–H), 2964 (C–H), 1599 (C‚N), 822 (C–Cl). 1H NMR
(DMSO-d6) d = 13.91 (s, 1H, SH), 13.76 (br s, 1H, NH),
9.48 (s, 1H, N‚CH), 8.52 (s, 1H, triazole-5H), 8.12 (s, 1H,
pyrazole-5H), 7.53–-7.81 (m, 4H, Ar–H). MS [EI] m/z 305
[M+1]. Elemental analysis (C12H9ClN6S); calcd. C, 47.29;
H, 2.98; N, 27.58; found C, 47.23; H, 2.94; N, 27.52%.
2.3.10. 4-({(E)-[3-(4-Fluorophenyl)-1H-pyrazol-4-yl]methyli-
dene}amino)-5-propyl-4H-1,2,4-triazole-3-thiol 3j
Yield 66%, m.p. 225–227 C. IR (cm1): 3154 (N–H), 3048
(Ar–H), 2963 (C–H), 1610 (C‚N), 1244 (C‚S), 1154 (C–F).
1H NMR (DMSO-d6) d = 13.71 (br s, 1H, SH&NH), 9.72
(s, 1H, N‚CH), 8.37 (s, 1H, pyrazole-5H), 7.33–7.79 (m,
4H, Ar–H), 2.64 (t, 2H, –CH2), 1.64 (m, 2H, –CH2), 0.92 (t,
3H, –CH3). MS [EI] m/z 331 [M+1]. Elemental analysis
(C15H15FN6S); calcd. C, 54.53; H, 4.58; N, 25.44; found C,
54.48; H, 4.51; N, 25.41%.
2.4. Antimicrobial studies
All the newly synthesized compounds were screened for their
antibacterial activity. For this, Staphylococcus aureus, Bacillus
subtilis, Escherichia coli and Pseudomonas aeruginosa microor-
ganisms were employed. Anti-microbial study was assessed by
Minimum Inhibitory concentration (MIC) by a serial dilution
method (Mackie and Cartney, 1989). Several colonies of S.
aureus, B. subtilis, E. coli and P. aeruginosa were picked off
338 S. Malladi et al.a fresh isolation plate and inoculated in corresponding tubes
containing 5 mL of trypticase soya broth. The broth was incu-
bated for 6 h at 37 C until there was visible growth. Mc Far-
land No. 5 standard was prepared by adding 0.05 mL of 1%
w/v BaCl2Æ2H2O in phosphate buffered saline (PBS) to
9.95 mL of 1% v/v H2SO4 in PBS. The growth of all the four
cultures was adjusted to Mc Farland No. 5 turbidity standard
using sterile PBS. This gives a 108 cfu/mL suspension. The
working inoculums of the aforementioned four different
microorganisms containing 105 cfu/mL suspension was pre-
pared by diluting the 108 cfu/mL suspension, 103 times in try-
pticase soya broth.
2.4.1. Preparation of anti-microbial suspension (1 mg/mL)
Dissolved 10 mg of each compound in 10 mL of dimethyl
formamide to get 1 mg/mL concentration.
2.4.2. Preparation of dilutions
In all, for each of the 10 anti-microbial compounds and stan-
dard anti-microbial i.e. Ceftriaxone, 24 tubes of 5 mL capac-
ity were arranged in 4 rows with each row containing 6 tubes.
Then 1.9 mL of trypticase soya broth was added in the ﬁrst
tube in each row and then 1 mL in the remaining tubes.
Now, 100 mL of anti-microbial suspension dissolved in di-
methyl formamide was added to the ﬁrst tube in each row
and then after mixing the content, 1 mL was serially trans-
ferred from these tubes to the second tube in each of the
rows. Then the contents in the second tube of each of the
rows were mixed and transferred to the third tube in each
of the rows.
This serial dilution was repeated till the sixth tube in each of
the rows. This provided anti-microbial concentrations of 50,
25, 12.5, 6.25, 3.125, 1.6125 mg/mL in the ﬁrst to sixth tube,
respectively, in each row. Finally, 1 mL of 105 cfu/mL
S. aureus, B. subtilis, E. coli and P. aeruginosa suspension
was added to the ﬁrst, second, third and fourth rows of tubes,
respectively. Along with the test samples and Ceftriaxone
(standard), the inoculums control (without antimicrobial
compound) and broth control (without anti-microbial com-
pound and inoculum) were maintained. All the test sample
and control tubes were then incubated for 16 h at 37 C.Table 1 Antibacterial data of Schiff bases in MIC.
Comp. No. S. aureus B. subti
3a 3.125 3.125
3b 3.125 3.125
3c 3.125 1.6125
3d 3.125 3.125
3e 12.5 3.125
3f 1.6125 1.6125
3g 12.5 12.5
3h 3.125 3.125
3i 6.25 12.5
3j 12.5 Growth
concent
Ceftriaxone
(Standard)
3.125 1.6125
Inoculum control Growth in all
concentrations
Growth
concent
Broth control No growth No grow2.4.3. Interpretation
After incubation, the tubes showing no visible growth were
considered to be representing the MIC. The details of results
are furnished in Table 1. Inoculums control showed visible
growth, where as broth control showed no growth.
3. Result and discussion
3.1. Chemistry
The route for the synthesis of Schiff bases 3a–j starting from
1a–c and 2a–e is illustrated in Scheme 1. The Schiff bases were
synthesized by the condensation of 4-amino-5-substituted-4H-
1,2,4-triazole-3-thiol (1a–c) with various 3-substituted-pyra-
zoles-4-carboxaldehydes (2a–c) in the presence of concentrated
sulfuric acid in ethanol-dioxane mixture. Structures of all syn-
thesized compounds in Scheme 1 were conﬁrmed on the basis
of IR, 1H NMR, mass and elemental analyses. The IR spec-
trum of compound 3a showed absorption bands at 3094,
3035, 2916, 1584 which were due to N–H, Ar–H, C–H and
C‚N groups, respectively. The 1H NMR spectrum of 3a
showed broad singlet at d 13.67 which was due to the presence
of S–H and N–H protons. The Schiff base proton i.e. N‚CH
and pyrazole-5H proton resonated as singlet at d 9.76 and
8.23, respectively. A quartet at d 2.69 and a triplet at d 1.21
conﬁrm the presence of alkyl side chain protons. The mass
spectrum of 3a showed molecular ion peak at m/z= 299
(M+1), which is in agreement with the molecular formula
C14H14N6S. Similarly the spectral values for all the compounds
and C, H, N analyses are given in the experimental part. Figs.
1 and 2 represents the IR spectrum and NMR spectrum of
compound 3d, respectively.
3.2. Antibacterial activity
All the newly synthesized compounds were screened for their
antibacterial activity. For this, S. aureus, B. subtilis, E. coli
and P. aeruginosa microorganisms were employed. Anti-
microbial study was assessed by Minimum Inhibitory concen-
tration (MIC) by serial dilution method. Antimicrobial resultslis E. coli P. aeruginosa
6.25 1.6125
1.6125 3.125
1.6125 1.6125
6.25 6.25
3.125 6.25
1.6125 1.6125
12.5 Growth in all
concentrations
12.5 6.25
12.5 6.25
in all
rations
Growth in all
concentrations
6.25
1.6125 1.6125
in all
rations
Growth in all
concentrations
Growth in all
concentrations
th No growth No growth
Figure 2 NMR spectrum of compound 3d.
Figure 1 IR spectrum of compound 3d.
Synthesis, characterization and antibacterial activity of some new pyrazole based Schiff bases 339indicate that, most of the synthesized compounds have shown
good to moderate activity against S. aureus, B. subtilis, E. coli
and P. aeruginosa microorganisms. In particular, compound 3f
has exhibited excellent activity against S. aureus whereas it has
shown activity equal to that of standard drug Ceftriaxone
against B. subtilis, E. coli and P. aeruginosa microorganisms.
In the case of compound 3c the activity was found to be equal
to that of standard drug Ceftriaxone for all four microorgan-
isms. Remaining compounds exhibited similar or moderate
antibacterial activity than compared to standard.
4. Conclusions
In the present work, a series of new pyrazole based Schiff bases
were synthesized and characterized by spectral studies. All the
synthesized compounds were evaluated for their antibacterial
activities against S. aureus, B. subtilis, E. coli and P. aeruginosa
microorganisms by serial dilution method. Compound 3f hasexhibited excellent activity against S. aureus as compared to
standard drug Ceftriaxone, whereas similar activity as that of
standard against remaining three microorganisms. Also com-
pound 3c was active at same concentration as that of the stan-
dard in case of all four microorganisms.Acknowledgements
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